Metformin Hydrochloride Tablets

DRUG4 trials

Sponsors

Xijing Hospital, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Fujian Shengdi Pharmaceutical Co., Ltd., Shandong Suncadia Medicine Co., Ltd.

Conditions

DiabetesEfficacyHealthy SubjectsNon-alcoholic Fatty Liver DiseaseType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

CompletedNCT04859452

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-05-26End: 2021-07-09Updated: 2021-07-20

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

CompletedNCT06654960

Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2024-11-05End: 2024-12-26Updated: 2025-01-07

Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human

Not yet recruitingNCT06727838

Shandong Suncadia Medicine Co., Ltd.Diabetes

Start: 2024-12-31End: 2025-05-31Target: 54Updated: 2024-12-11

Phase 4

Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

CompletedNCT03796975

Xijing HospitalEfficacy, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus

Start: 2018-06-28End: 2019-11-20Updated: 2020-08-07

Related Papers

Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study

Journal of Diabetes Research2023-06-0110 citations